tradingkey.logo

Rxsight Inc

RXST
查看詳細走勢圖
8.390USD
+0.570+7.29%
收盤 02/06, 16:00美東報價延遲15分鐘
344.67M總市值
虧損本益比TTM

Rxsight Inc

8.390
+0.570+7.29%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+7.29%

5天

-3.45%

1月

-12.79%

6月

+7.70%

今年開始到現在

-19.48%

1年

-74.61%

查看詳細走勢圖

TradingKey Rxsight Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Rxsight Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業中等水平。增長潛力較大。當前估值合理,在醫療設備與耗材行業排名85/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為10.39。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Rxsight Inc評分

相關信息

行業排名
85 / 205
全市場排名
233 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Rxsight Inc亮點

亮點風險
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
業績高增長
公司營業收入穩步增長,連續3年增長185.54%
估值高估
公司最新PE估值-9.57,處於3年歷史高位
機構減倉
最新機構持股34.25M股,環比減少29.81%
貝利・吉福德持倉
明星投資者貝利・吉福德持倉,最新持倉693.15K股

分析師目標

基於 11 分析師
持有
評級
10.389
目標均價
+30.84%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Rxsight Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Rxsight Inc簡介

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
公司代碼RXST
公司Rxsight Inc
CEOKurtz (Ron M)
網址https://www.rxsight.com/
KeyAI